All In Biotech

Drug Trial Radar · NCT06172322

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

A Phase Ib/Ⅱ Study of Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of NTQ1062 Tablets in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

42

Planned (sponsor's estimate)

Start

Dec 28, 2023

Primary completion

Apr 2025

Study completion Jul 2025

Sponsor

Sponsor type
Industry
First posted
Dec 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or metastatic HR positive/HER-2 negative breast cancer.

Conditions

  • HR Positive/HER-2 Negative Breast Cancer

Interventions

  • NTQ1062 with FulvestrantDrug

    Drug: NTQ1062 tablet(s) ,PO,QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment). Drug: Fulvestrant Injection 500mg in a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: First treatment cycle ( 28 days)
  2. Recommended phase 2 dose (RP2D)Time frame: Through study completion, an average of 1 year
  3. Adverse eventsTime frame: Through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.